业绩快报显示，2024年末，悦康药业对产品"银杏叶提取物注射液"价格及销售策略进行调整，对收入和 利润呈现阶段性较大影响。同时，报告期内，研发费用同比上升，高比例的研发投入对净利润产生了一 定影响。 北京商报讯（记者 王寅浩 宋雨盈）2月27日，悦康药业发布2025年业绩快报，2025年度公司实现营业总 收入24.46亿元，同比下降35.3%；归属于母公司所有者的净亏损为2.54亿元，同比下降305.18%；归属 于母公司所有者的扣除非经常性损益的净亏损为2.8亿元，同比下降352.83%。 ...

2月3日，悦康药业跌0.59%，截至发稿，报21.93元/股，成交2.77亿元，换手率2.86%，总市值98.69亿 元。悦康药业股价已经连续7天下跌，区间累计跌幅19.23%。 资料显示，悦康药业集团股份有限公司位于北京市北京经济技术开发区宏达中路6号,香港铜锣湾希慎道 33号利园1期19楼1919室，成立日期2001年8月14日，上市日期2020年12月24日，公司主营业务涉及悦康 药业定位于高端化学药的研发与生产,报告期内主营业务收入主要集中在心脑血管药物、消化系统药 物、糖尿病用药以及抗感染药物等。银杏叶提取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑 肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠、注射用头孢曲松钠对公司收入贡献占比较大或未 来增长潜力较大,是公司的主要产品。主营业务收入构成为：心脑血管类55.67%，抗感染20.88%，原料 药8.73%，消化系统类6.87%，降糖类4.85%，其他2.62%，其他(补充)0.36%，技术服务0.02%。 责任编辑：小浪快报 数据显示，华富基金旗下1只基金重仓悦康药业。华富健康文娱灵活配置混合A（001563）四季度持有 股数52万股，占基金净 ...

2月2日，悦康药业跌5.15%，截至发稿，报23.01元/股，成交9003.05万元，换手率0.85%，总市值103.55 亿元。悦康药业股价已经连续5天下跌，区间累计跌幅10.64%。 资料显示，悦康药业集团股份有限公司位于北京市北京经济技术开发区宏达中路6号,香港铜锣湾希慎道 33号利园1期19楼1919室，成立日期2001年8月14日，上市日期2020年12月24日，公司主营业务涉及悦康 药业定位于高端化学药的研发与生产,报告期内主营业务收入主要集中在心脑血管药物、消化系统药 物、糖尿病用药以及抗感染药物等。银杏叶提取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑 肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠、注射用头孢曲松钠对公司收入贡献占比较大或未 来增长潜力较大,是公司的主要产品。主营业务收入构成为：心脑血管类55.67%，抗感染20.88%，原料 药8.73%，消化系统类6.87%，降糖类4.85%，其他2.62%，其他(补充)0.36%，技术服务0.02%。 从悦康药业十大流通股东角度 易方达医疗保健行业混合A（110023）基金经理为杨桢霄。 截至发稿，杨桢霄累计任职时间9年169天，现 ...

公司2024年末对产品"银杏叶提取物注射液"价格及销售策略进行调整，该事项对公司收入和利润呈现阶 段性较大的影响。公司坚持长期发展战略，不断调整和完善经营策略，提升运营效率，同时逐步优化销 售策略，维护核心销售渠道的稳定，持续增强公司核心竞争力和投资价值。报告期内，公司继续保持高 比例研发投入，研发费用同比上升，高比例的研发投入对公司净利润产生了一定影响。 智通财经APP讯，悦康药业(688658.SH)发布2025年年度业绩预亏公告，预计2025年年度实现归属于母 公司所有者的净利润为-28,000万元到-23,500万元，与上年同期(法定披露数据)相比，将出现亏损。 ...

Core Viewpoint - Yuyuan Pharmaceutical is forecasting a net loss attributable to shareholders of the parent company for 2025, ranging from 235 million to 280 million yuan, indicating a decline compared to the previous year [1] Financial Performance - The expected net loss, excluding non-recurring gains and losses, is projected to be between 260 million and 305 million yuan [1] - The anticipated financial downturn is attributed to adjustments in pricing and sales strategies for the product "Ginkgo Leaf Extract Injection" at the end of 2024 [1] R&D Expenses - The increase in research and development expenses year-on-year is expected to have a significant impact on net profit [1]

每经AI快讯，悦康药业1月30日晚间发布业绩预告，悦康药业集团股份有限公司预计2025年年度实现归 属于母公司所有者的净利润为-2.8亿元到-2.35亿元，与上年同期相比，将出现亏损。业绩变动主要原因 是，公司2024年末对产品"银杏叶提取物注射液"价格及销售策略进行调整，该事项对公司收入和利润呈 现阶段性较大的影响。公司坚持长期发展战略，不断调整和完善经营策略，提升运营效率，同时逐步优 化销售策略，维护核心销售渠道的稳定，持续增强公司核心竞争力和投资价值。公司坚定将研发创新置 于战略核心地位，持续积极推动新药研发项目。报告期内，公司继续保持高比例研发投入，研发费用同 比上升，高比例的研发投入对公司净利润产生了一定影响。 （记者 曾健辉） 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 ...

悦康药业公告称，预计2025年年度归属于母公司所有者的净利润为-2.80亿元到-2.35亿元，上年同期为 1.24亿元；扣非净利润为-3.05亿元到-2.60亿元，上年同期为1.11亿元。业绩预亏主要因2024年末对"银 杏叶提取物注射液"价格及销售策略调整，对收入和利润产生阶段性较大影响，且报告期内研发费用同 比上升。具体数据以最终审计结果为准。 ...

Core Viewpoint - Yuekang Pharmaceutical Group Co., Ltd. has submitted an application for H-share listing on the Hong Kong Stock Exchange, marking a significant step in its "A+H" dual-platform listing strategy, which aims to address its financial challenges and support R&D innovation [1][3]. Group 1: Company Overview - Yuekang Pharmaceutical, listed on the STAR Market, is transitioning to a dual listing in Hong Kong to create an international financing platform [1][3]. - The company has faced declining performance, with revenue dropping from 4.542 billion yuan in 2022 to 3.781 billion yuan in 2024, and net profit plummeting from 335 million yuan to 124 million yuan in the same period [6][7]. Group 2: Financial Challenges - The company's core product, Ginkgo Biloba Extract Injection, has seen a price reduction of approximately 53% due to regulatory scrutiny, leading to significant revenue loss and a quarterly loss of 86.01 million yuan in Q4 2024 [6][7]. - The reliance on a single product has weakened the company's risk resilience, exposing vulnerabilities in its product pipeline [7]. Group 3: Strategic Initiatives - The funds raised from the H-share listing are intended for R&D innovation and operational capital, which could alleviate financial pressures and revitalize stalled projects [10]. - The dual listing structure is expected to enhance liquidity and provide a valuation anchor based on the existing A-share market [10]. Group 4: Market Sentiment and Risks - Investors are cautious, weighing the potential for recovery against ongoing risks, including high sales costs and governance concerns stemming from the controlling shareholder's legal issues [9][11]. - The market perceives the recent price adjustments as a potential turning point, suggesting that the worst may be over, but uncertainties regarding profitability recovery remain [10][11]. Group 5: IPO Details - The IPO timeline is pending, with details such as the offering price and allocation mechanisms yet to be announced [13]. - The company plans to establish a green shoe mechanism to stabilize pricing, allowing underwriters to exercise an over-allotment option of up to 15% of the initial offering size [13].

Core Viewpoint - The Hong Kong stock market is set to welcome Yuyuan Pharmaceutical Group Co., Ltd. as it officially submitted its H-share listing application to the Hong Kong Stock Exchange, marking a significant step in its dual-platform listing strategy [1][3]. Group 1: Company Overview - Yuyuan Pharmaceutical, listed on the STAR Market, aims to establish an international financing platform through its H-share listing, which is crucial for its research and development innovation and operational funding [3]. - The company has faced significant challenges, including a decline in revenue and profitability, with revenue dropping from 4.542 billion yuan in 2022 to 3.781 billion yuan in 2024, and net profit plummeting from 335 million yuan to 124 million yuan in the same period [6]. Group 2: Financial Performance - The company recorded a net loss of 49.27 million yuan in the first quarter of 2025, indicating ongoing financial difficulties [6]. - The decline in performance is primarily attributed to the price reduction of its flagship product, Ginkgo Biloba Extract Injection, which saw a price drop of approximately 53% due to regulatory scrutiny, leading to a quarterly loss of 86.01 million yuan in Q4 2024 [6]. Group 3: Business Structure and Challenges - Yuyuan Pharmaceutical's heavy reliance on a single product has weakened its risk resilience, with the Ginkgo product historically contributing nearly 60% of its revenue [7]. - The transition from generic drugs to innovative drugs has been slow, with only one new drug launched and several research projects delayed [7]. - The company has incurred high sales expenses, totaling 7.37 billion yuan from 2021 to 2024, raising concerns about its sales model and compliance [7]. Group 4: Market Sentiment and Investment Considerations - Investors are weighing the potential for a turnaround against ongoing risks, with the company's future performance heavily dependent on its ability to stabilize and innovate [9][10]. - The H-share fundraising is intended for R&D and operational support, which could alleviate financial pressures and revitalize stalled projects [10]. - The dual-listing structure may provide a valuation anchor and enhance liquidity, although the H-share price is expected to be at a discount to the A-share price [10]. Group 5: Upcoming IPO Details - The IPO timeline is yet to be announced, with the application currently under review [13]. - The total amount to be raised and the share price range are still pending, with the issuance expected to not exceed 15% of the total share capital post-issue [13]. - The presence of cornerstone investors will be a key indicator of market confidence in the company's recovery prospects [13].

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its competitiveness and international brand image while diversifying its financing channels [1][2]. Group 1: Company Overview - Yuyuan Pharmaceutical Group Co., Ltd. was established in 2001 and is headquartered in Beijing, focusing on new drug research and development, production, distribution, and international trade [2]. - The company has developed nine core R&D platforms, including nucleic acid drugs, peptide drugs, traditional Chinese medicine innovation, and high-end chemical drugs [2]. Group 2: Financial Performance - The company has faced challenges with its fundraising projects, with a total of 2.192 billion yuan raised in its IPO, which has not led to sustained growth due to project delays [2][4]. - Yuyuan Pharmaceutical's net profit has declined for three consecutive years from 2022 to 2024, with decreases of 38.53%, 44.87%, and 33.05% respectively [4]. - In the first three quarters of 2025, the company reported total revenue of 1.759 billion yuan, a year-on-year decrease of 41.20%, and a net loss of 148 million yuan compared to a profit of 210 million yuan in the same period last year [6]. Group 3: Recent Developments - The company announced plans to raise up to 300 million yuan through a private placement to support its main business and supplement working capital [3]. - Yuyuan Pharmaceutical's core product, Ginkgo biloba extract injection, faced controversy over pricing, leading to a significant revenue drop of 36% in Q4 2024 and a net loss of 86.01 million yuan [3]. - The company's major shareholder, the Wei family, is facing issues with forced selling of shares, with 26.5 million shares auctioned for a total of 486 million yuan [7].